Ninety One UK Ltd Has $37.98 Million Stake in Edwards Lifesciences Co. (NYSE:EW)

Ninety One UK Ltd increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 2,740.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 498,029 shares of the medical research company’s stock after buying an additional 480,496 shares during the period. Ninety One UK Ltd owned 0.08% of Edwards Lifesciences worth $37,975,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in EW. Castleview Partners LLC acquired a new position in shares of Edwards Lifesciences in the first quarter valued at $25,000. Compass Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at $31,000. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at $34,000. Jackson Grant Investment Advisers Inc. acquired a new position in shares of Edwards Lifesciences in the third quarter valued at $38,000. Finally, Janiczek Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 108.6% in the third quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 303 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have commented on the stock. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Truist Financial boosted their target price on shares of Edwards Lifesciences from $78.00 to $84.00 and gave the company a “buy” rating in a research report on Friday, December 22nd. Morgan Stanley boosted their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. Finally, Evercore ISI boosted their target price on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $91.73.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the completion of the sale, the vice president now owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,000 shares of the stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total transaction of $944,130.00. Following the transaction, the vice president now directly owns 39,503 shares in the company, valued at approximately $3,390,542.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at $16,049,739.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 194,004 shares of company stock valued at $17,166,254. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $86.45 on Friday. The business has a 50 day moving average of $90.14 and a 200-day moving average of $78.19. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40. The company has a market capitalization of $52.04 billion, a P/E ratio of 37.59, a P/E/G ratio of 4.32 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter in the prior year, the firm posted $0.64 earnings per share. The firm’s revenue was up 13.3% compared to the same quarter last year. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.